Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the quarter ended 31st December, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Trident Lifeline, a Surat-based pharmaceutical formulations exporter focused on Africa, Latin America, CIS and East Asia, reported strong Q3FY26 standalone numbers. Revenue rose 44% YoY to ₹24.56 crore, with EBITDA up 53% to ₹7.17 crore and EBITDA margin expanding 177 basis points to 29%. Profit after tax grew 33% YoY to ₹4.01 crore (EPS ₹3.47). For 9MFY26, revenue grew 50% to ₹72.46 crore and PAT was up 32% to ₹12.08 crore, though 9M EBITDA margin contracted 179 bps to 27% versus the prior year. The company has 3,528 products in its portfolio, presence in 44 countries, 1,070 active registrations and a pipeline of 2,458 registrations awaiting approval. Management said the outlook remains strong and growth will be driven by a mix of organic and inorganic expansion through its hybrid manufacturing and acquisition strategy.
Shareholders saw robust top-line and bottom-line growth in Q3 with margin expansion, but 9M EBITDA margin compression and rising finance costs and depreciation flag near-term cost pressures. The strong registration pipeline and management's positive outlook on combined organic and inorganic growth could support future revenue scaling.